RXRX
insider transactionsRECURSION PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-58.0K
0 buy · 58.0K sell
Net value · 30d
-$210.4K
$0 in · $210.4K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
3
0 buy · 58.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Ben R Taylor KEY
Chief Financial Officer
$17.0K
5.4K sh · $3.15
Own -0%
-
Sell·S
Najat Khan KEY
CEO and President · 10b5-1
$84.5K
23.6K sh · $3.58
Own -1%
-
Sell·S
Director · 10b5-1
$15.5K
4.4K sh · $3.54
Own -9%
-
Sell·S
Director · 10b5-1
$110.4K
30.0K sh · $3.68
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Ben R Taylor KEY | Other F | 5.4K | $17.0K |
| Jun 5, 2026 | Najat Khan KEY 10b5-1 | Sell S | 23.6K | $84.5K |
| Jun 3, 2026 | Namandje Bumpus 10b5-1 | Sell S | 4.4K | $15.5K |
| Jun 2, 2026 | Blake Borgeson 10b5-1 | Sell S | 30.0K | $110.4K |
About RXRX insider trading
This page tracks insider transactions for RECURSION PHARMACEUTICALS, INC. (RXRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.